

University of Dundee

Comparative Prognostic Utility of Indexes of Microvascular Function Alone or in Combination in Patients with an Acute ST-Segment-Elevation Myocardial Infarction

Carrick, David; Haig, Caroline; Ahmed, Nadeem; Carberry, Jaclyn; Yue May, Vannesa Teng; McEntegart, Margaret

Published in:
Circulation

DOI:
[10.1161/CIRCULATIONAHA.116.022603](https://doi.org/10.1161/CIRCULATIONAHA.116.022603)

Publication date:
2016

Licence:
CC BY

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Carrick, D., Haig, C., Ahmed, N., Carberry, J., Yue May, V. T., McEntegart, M., Petrie, M. C., Eteiba, H., Lindsay, M., Hood, S., Watkins, S., Davie, A., Mahrous, A., Mordi, I., Ford, I., Radjenovic, A., Oldroyd, K. G., & Berry, C. (2016). Comparative Prognostic Utility of Indexes of Microvascular Function Alone or in Combination in Patients with an Acute ST-Segment-Elevation Myocardial Infarction. *Circulation*, 134(23), 1833-1847. <https://doi.org/10.1161/CIRCULATIONAHA.116.022603>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Comparative Prognostic Utility of Indexes of Microvascular Function Alone or in Combination in Patients With an Acute ST-Segment–Elevation Myocardial Infarction

BACKGROUND: Primary percutaneous coronary intervention is frequently successful at restoring coronary artery blood flow in patients with acute ST-segment–elevation myocardial infarction; however, failed myocardial reperfusion commonly passes undetected in up to half of these patients. The index of microvascular resistance (IMR) is a novel invasive measure of coronary microvascular function. We aimed to investigate the pathological and prognostic significance of an $\text{IMR} > 40$, alone or in combination with a coronary flow reserve ($\text{CFR} \leq 2.0$), in the culprit artery after emergency percutaneous coronary intervention for acute ST-segment–elevation myocardial infarction.

METHODS: Patients with acute ST-segment–elevation myocardial infarction were prospectively enrolled during emergency percutaneous coronary intervention and categorized according to IMR (≤ 40 or > 40) and CFR (≤ 2.0 or > 2.0). Cardiac magnetic resonance imaging was acquired 2 days and 6 months after myocardial infarction. All-cause death or first heart failure hospitalization was a prespecified outcome (median follow-up, 845 days).

RESULTS: IMR and CFR were measured in the culprit artery at the end of percutaneous coronary intervention in 283 patients with ST-segment–elevation myocardial infarction (mean \pm SD age, 60 ± 12 years; 73% male). The median IMR and CFR were 25 (interquartile range, 15–48) and 1.6 (interquartile range, 1.1–2.1), respectively. An $\text{IMR} > 40$ was a multivariable associate of myocardial hemorrhage (odds ratio, 2.10; 95% confidence interval, 1.03–4.27; $P = 0.042$). An $\text{IMR} > 40$ was closely associated with microvascular obstruction. Symptom-to-reperfusion time, TIMI (Thrombolysis in Myocardial Infarction) blush grade, and no ($\leq 30\%$) ST-segment resolution were not associated with these pathologies. An $\text{IMR} > 40$ was a multivariable associate of the changes in left ventricular ejection fraction (coefficient, -2.12 ; 95% confidence interval, -4.02 to -0.23 ; $P = 0.028$) and left ventricular end-diastolic volume (coefficient, 7.85; 95% confidence interval, 0.41–15.29; $P = 0.039$) at 6 months independently of infarct size. An $\text{IMR} > 40$ (odds ratio, 4.36; 95% confidence interval, 2.10–9.06; $P < 0.001$) was a multivariable associate of all-cause death or heart failure. Compared with an $\text{IMR} > 40$, the combination of $\text{IMR} > 40$ and $\text{CFR} \leq 2.0$ did not have incremental prognostic value.

CONCLUSIONS: An $\text{IMR} > 40$ is a multivariable associate of left ventricular and clinical outcomes after ST-segment–elevation myocardial infarction independently of the infarction size. Compared with standard clinical measures of the efficacy of myocardial reperfusion, including the ischemic time, ST-segment elevation, angiographic blush grade, and CFR, IMR has superior clinical value for risk stratification and may be considered a reference test for failed myocardial reperfusion.

CLINICAL TRIAL REGISTRATION: URL: <https://www.clinicaltrials.gov>. Unique identifier: NCT02072850.

David Carrick, PhD*
Caroline Haig, PhD*
Nadeem Ahmed, MBChB
Jaclyn Carberry, BMedSci
Vannessa Teng Yue May, BMedSci
Margaret McEntegart, PhD
Mark C. Petrie, MBChB
Hany Eteiba, MD
Mitchell Lindsay, MD
Stuart Hood, MD
Stuart Watkins, MD
Andrew Davie, MD
Ahmed Mahrous, MD
Ify Mordi, MD
Ian Ford, PhD
Aleksandra Radjenovic, PhD
Keith G. Oldroyd, MD(Hons)
Colin Berry, PhD

*Drs Carrick and Haig contributed equally.

Correspondence to: Colin Berry, PhD, BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, 126 University Place, University of Glasgow, Glasgow, G12 8TA, Scotland, UK. E-mail colin.berry@glasgow.ac.uk

Sources of Funding, see page 1844

Key Words: magnetic resonance imaging ■ microcirculation ■ myocardial infarction ■ prognosis

© 2016 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Clinical Perspective

What Is New?

- The index of microvascular resistance (IMR) and coronary flow reserve were routinely measured in the culprit coronary artery of a reasonably large cohort of patients with acute ST-segment–elevation myocardial infarction treated by emergency percutaneous coronary intervention.
- Compared with ischemic time and angiographic and electrocardiographic measures of reperfusion, an IMR>40 was more consistently and strongly associated with microvascular pathology, changes in left ventricular function and volumes, and all-cause death and heart failure in the longer term.
- Compared with an IMR>40, the combination of IMR>40 and coronary flow reserve ≤ 2.0 did not have additional prognostic value.

What Are the Clinical Implications?

- Despite the routine success of primary percutaneous coronary intervention, failed myocardial reperfusion is common and usually passes undetected.
- IMR has emerging clinical utility as a routine test for the efficacy of myocardial reperfusion in invasively managed patients with acute ST-segment–elevation myocardial infarction.
- An IMR>40 represents a prognostically validated reference test for failed myocardial reperfusion at the end of primary percutaneous coronary intervention.
- Our results confirm previous investigations and support further research into IMR-based therapeutic strategies in patients with acute ST-segment–elevation myocardial infarction.

Despite the success of emergency percutaneous coronary intervention (PCI) in restoring coronary blood flow in patients with acute ST-segment–elevation myocardial infarction (STEMI), a failure of myocardial reperfusion, which manifests initially as microvascular obstruction and then subsequently as myocardial hemorrhage, affects approximately half of patients with acute STEMI.^{1,2} Microvascular pathology (specifically, microvascular obstruction and myocardial hemorrhage) revealed by cardiac magnetic resonance (CMR) is prognostically important^{3–5}; however, CMR is neither feasible acutely nor routinely recommended. Established tests for failed reperfusion such as the surface ECG, a test focused on ST-segment resolution and performed 60 to 90 minutes after reperfusion,⁶ and the angiographic tissue myocardial perfusion grade^{7,8} lack sensitivity and reproducibility in routine practice.⁹ Failed myocardial reperfusion passes undetected in up to half of patients after acute STEMI.^{3,4}

Invasive assessment of microcirculatory function at the end of emergency PCI before the patient is transferred to the ward presents an opportunity to identify STEMI patients

with failed myocardial reperfusion with greater accuracy than the angiogram or the ECG. The index of microvascular resistance (IMR) is independently associated with left ventricular (LV) function¹⁰ and infarct pathology,^{11,12} and in a recent study, an IMR>40 was a multivariable associate of mortality after STEMI.¹³ Coronary flow reserve (CFR) reflects epicardial and microvascular vasodilator capacity.¹⁴ CFR is associated with composite cardiovascular outcomes, including revascularization, in patients with stable coronary disease¹⁵ and after acute STEMI.¹⁶ We have recently shown that IMR is more closely associated with severe microvascular pathology, LV remodeling, and health outcome than either the angiogram or CFR,¹⁷ but whether the combination of IMR and CFR adds prognostic value is uncertain.

Different IMR cutoffs have been proposed,^{10–13} but only an IMR>40 is associated with mortality.¹³ The combination of an increased IMR and reduced CFR has been associated with enhanced detection of microvascular obstruction¹⁸ and viability and prognosis.¹⁶ However, in that study, only 10 major adverse cardiac and cerebrovascular events occurred, of which 5 were revascularizations. Changes in IMR and CFR within 24 hours after reperfusion have been associated with LV ejection fraction (LVEF).^{19,20} However, prior studies are limited by sample size ($n=27–45$ subjects),^{10,20–22} short follow-up (3–6 months),^{10,18,20–22} lack of association with spontaneous hard outcomes,¹⁶ and differences in cutoffs,^{12,23} supporting the case for definitive research.

Building on prior literature, we hypothesized that in patients with an acute STEMI, an IMR>40 would be more closely associated with infarct pathology and clinical outcomes than established angiographic and ECG measures of myocardial reperfusion and that, compared with IMR alone, the combination of an IMR>40 and a CFR ≤ 2.0 might be more closely associated with infarct pathologies and prognosis. We measured IMR and CFR simultaneously in the culprit coronary artery immediately after emergency PCI in a large, unselected population of patients with acute STEMI.

METHODS

Study Population and STEMI Management

We performed a prospective cohort study in a regional cardiac center between July 14, 2011, and November 22, 2012. Two hundred eighty-eight patients with STEMI were enrolled by 13 cardiologists. The patients provided written informed consent to undergo a diagnostic guidewire-based assessment after reperfusion and then CMR 2 days and 6 months later, as well as follow-up for health outcomes in the longer term.

Patients were eligible if they had an indication for primary PCI or thrombolysis for acute STEMI.^{24,25} Exclusion criteria included standard contraindications to CMR, for example, a pacemaker. The study was approved by the National Research Ethics Service (reference 10-S0703-28). Acute STEMI management ([Methods in the online-only Data Supplement](#)) followed contemporary guidelines.^{24,25} The ClinicalTrials.gov identifier is NCT02072850.

Measurement of CFR and IMR in the Culprit Coronary Artery at the End of PCI

We adopted a thermodilution technique rather than Doppler because we wished to implement a method that is most transferable to routine clinical practice. In our experience, the Doppler measurements can be more time-consuming, require considerable experience, and may be less reproducible,¹⁴ and the guidewire is typically more expensive.

A coronary pressure- and temperature-sensitive guide wire (St. Jude Medical, St. Paul, MN) was used to measure IMR and CFR in the culprit coronary artery at the end of primary or rescue PCI. The guidewire was calibrated outside the body, equalized with aortic pressure at the ostium of the guide catheter, and then advanced to the distal third of the culprit artery. This thermodilution method is based on the following basic relationship: flow=volume/mean transit time. CFR is defined as the ratio of peak hyperemic to resting flow (CFR=flow at hyperemia/flow at rest). Flow is the ratio of the volume (V) divided by the mean transit time (Tmn). Thus, CFR can be expressed as follows: CFR=(V/Tmn) at hyperemia/(V/Tmn) at rest. Assuming that the epicardial volume remains unchanged, CFR can be calculated as follows: CFR=Tmn at rest/Tmn at hyperemia. CFR and IMR are distinct physiological parameters. CFR reflects epicardial and microcirculatory function. In contrast, IMR is a direct invasive measure of microvascular resistance. IMR is defined as the distal coronary pressure multiplied by the mean transit time of a 3-mL bolus of saline at room temperature during maximal coronary hyperemia measured simultaneously (mm Hg·s or units).^{10–12}

Hyperemia was induced by 140 $\mu\text{g}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ of intravenous adenosine preceded by a 2-mL intracoronary bolus of 200 μg nitrate. The mean aortic and distal coronary pressures were recorded during maximal hyperemia. We have previously found IMR to be highly repeatable when assessed by duplicate measurements 5 minutes apart in 12 consecutive patients with STEMI at the end of PCI.¹²

On the basis of prior literature, we prespecified and examined an IMR>40 and the following classifications: (1) IMR≤40 and CFR>2.0, (2) IMR>40 and CFR>2.0, (3) IMR≤40 and CFR≤2.0, and (4) IMR>40 and CFR≤2.0.

CMR Imaging

We used CMR to provide reference data on LV function, pathology, and surrogate outcomes independently of the invasive tests (Figure 1). CMR was performed on a Siemens MAGNETOM Avanto (Erlangen, Germany) 1.5-T scanner with a 12-element phased-array cardiac surface coil.²⁶ The imaging protocol^{5,27} (Methods in the online-only Data Supplement) included cine magnetic resonance imaging with steady-state free precession, T2 mapping,^{28,29} T2* mapping, and delayed-enhancement phase-sensitive inversion-recovery pulse sequences.³⁰ The scan acquisitions were spatially coregistered and included different slice orientations to enhance diagnostic confidence.

Imaging Analyses

The CMR analyses are described in detail in [Methods in the online-only Data Supplement](#).

Infarct Definition and Size

The presence of acute infarction was established on the basis of abnormalities in cine wall motion, rest first-pass myocardial perfusion, and delayed-enhancement imaging in 2 imaging planes. The myocardial mass of late gadolinium (grams) was quantified with computer-assisted planimetry, and the territory of infarction was delineated with the use of a signal intensity threshold of >5 SD above a remote reference region and expressed as a percentage of total LV mass.³¹

Microvascular Obstruction

Microvascular obstruction was defined as a dark zone on early gadolinium enhancement imaging 1, 3, 5, and 7 minutes after contrast injection that remained present within an area of late gadolinium enhancement at 15 minutes.

Myocardial Edema

The extent of myocardial edema was defined as LV myocardium with pixel values (T2) >2 SD from remote myocardium.^{28,29,32–35}

Myocardial Salvage

Myocardial salvage was calculated by subtracting the percent infarct size from percent area at risk, as reflected by the extent of edema.^{12,32,35} The myocardial salvage index was calculated by dividing the myocardial salvage area by the initial area at risk.

LV Remodeling

An increase in LV volume at 6 months from baseline was taken to reflect LV remodeling.^{27,35,36} Adverse remodeling was defined as an increase in LV end-diastolic volume (LVEDV) ≥20% at 6 months from baseline.²⁷

Myocardial Hemorrhage

On the T2* CMR maps, a region of reduced signal intensity within the infarcted area with a T2* value of <20 milliseconds^{4,37–40} was considered to confirm the presence of myocardial hemorrhage.

Electrocardiography

A 12-lead ECG was obtained before coronary reperfusion and 60 minutes afterward. The extent of ST-segment resolution on the ECG assessed 60 minutes after reperfusion compared with the baseline ECG before reperfusion⁴¹ was expressed as complete (≥70%), incomplete (30%–<70%), or none (≤30%).

Coronary Angiogram Acquisition and Analyses

Coronary angiograms were acquired during usual care with cardiac catheter laboratory x-ray (Innova, GE Healthcare) and information technology equipment (Centricity, GE Healthcare). The angiograms were analyzed by trained observers (J.C., V.T.Y.M) who were blinded to all other clinical and MRI data. The TIMI (Thrombolysis in Myocardial Infarction) coronary flow grade⁴² and frame count⁴³ were assessed at initial angiography and at the end of the procedure. TIMI myocardial perfusion grade⁴⁴ was assessed at the end of the procedure (Methods in the online-only Data Supplement).




Figure 1. Four patients with acute ST-segment-elevation myocardial infarction treated by primary percutaneous coronary intervention (PCI).

Each patient had index of microvascular resistance (IMR) and coronary flow reserve (CFR) measured in the culprit coronary artery at the end of the procedure. The patients reflect the following categories: $\text{IMR} \leq 40$ and $\text{CFR} > 2.0$; $\text{IMR} \leq 40$ and $\text{CFR} \leq 2.0$; $\text{IMR} > 40$ and $\text{CFR} > 2.0$; and $\text{IMR} > 40$ and $\text{CFR} \leq 2.0$. The patients were treated with similar antithrombotic therapy, including aspirin, clopidogrel, heparin, and intravenous glycoprotein IIb/IIIa inhibitor therapy with tirofiban. Each patient had normal TIMI (Thrombolysis in Myocardial Infarction) grade 3 flow at the end of PCI. Cardiac magnetic resonance imaging (MRI) was performed for each patient 2 days later. **A**, A patient with a normal IMR and a normal CFR. Invasive assessment of microvascular function in the culprit coronary artery at the end of primary PCI indicated that microcirculatory function was preserved. Cardiac magnetic resonance (CMR) subsequently revealed nontransmural late gadolinium enhancement consistent with salvaged myocardium. There was no evidence of myocardial hemorrhage (**middle right**) or microvascular obstruction (**right**). **B**, A patient with a normal IMR and a low CFR. Late gadolinium contrast CMR revealed transmural inferior myocardial infarction with a small central zone of hypointense microvascular obstruction (**arrow, right**). T2^* -CMR excluded myocardial hemorrhage within the infarct core (**middle right**). **C**, A patient with a high IMR and a normal CFR. Late gadolinium contrast-enhanced CMR revealed transmural anteroseptal myocardial infarction complicated by microvascular obstruction (**arrow, right**). T2^* -CMR (**arrow, middle right**) revealed myocardial hemorrhage within the infarct core, and microvascular obstruction spatially corresponded with the myocardial hemorrhage. **D**, A patient with a high IMR and a low CFR. Invasive guidewire-based physiological testing at the end of primary PCI revealed severe microvascular dysfunction. Transmural myocardial infarction and microvascular obstruction are present, in association with abundant myocardial hemorrhage (**arrow, middle right**).

Laboratory Analyses

The acquisition of blood samples for biochemical and hematologic analyses is described in [Methods in the online-only Data Supplement](#).

Prespecified Health Outcomes

We prespecified adverse health outcomes that are pathophysiologically linked with STEMI.^{45,46} The primary composite outcome was all-cause death or first heart failure event after

the initial hospitalization (Methods in the online-only Data Supplement).

Statistical Analyses

The sample size calculation and statistical methods are described in the Methods in the online-only Data Supplement. Random-effects models were used to compute interrater and intrarater reliability measures (intraclass correlation coefficient) for the reliability of angiographic measures of myocardial reperfusion measured independently by 2 observers in 20 randomly selected patients from the cohort (Results in the online-only Data Supplement). All *P* values are 2-sided, and value of *P* > 0.05 indicates the absence of a statistically significant effect. Statistical analyses were performed with R version 2.15.1, SAS version 9.3, or higher versions of these programs.

RESULTS

Patient Characteristics and IMR and CFR Measured Acutely in the Culprit Coronary Artery After Reperfusion

A total of 283 patients with STEMI had IMR and CFR measured in the culprit coronary artery at the end of emergency PCI (Table 1 and Figure 2). The median IMR and CFR were 25 (interquartile range, 15–48) and 1.6 (interquartile range, 1.1–2.1), respectively. A CFR ≤ 2.0, an IMR > 40, or both occurred in 210 (74%), 79 (28%) (Table 1), and 65 (23%) patients, respectively (Table I in the online-only Data Supplement).

CMR Findings

CMR imaging occurred 2.1 ± 1.8 days later, and 264 patients (93%) had follow-up CMR at 6 months (Table 2 and Figure 2). Case examples are shown in Figure 1. Myocardial hemorrhage and microvascular obstruction occurred in 89 (42%) and 114 (54%) patients, respectively. An IMR > 40 (Table 2) and the combination of an IMR > 40 and a CFR ≤ 2.0 (Table II in the online-only Data Supplement) were associated with LVEF and infarct pathology 2 days after MI and LVEF at 6 months.

Multivariable Associations for an IMR > 40 With Microvascular Infarct Pathology Revealed by CMR

Myocardial Hemorrhage

In a binary logistic regression model with baseline characteristics, an IMR > 40 was a multivariable associate of myocardial hemorrhage (odds ratio [OR], 2.86; 95% confidence interval [CI], 1.52–5.39; *P* = 0.001; Table 3), whereas symptom-to-reperfusion time, TIMI blush grade, and no ST-segment resolution were not.

Microvascular Obstruction

An IMR > 40 was a multivariable associate of microvascular obstruction (OR, 2.82; 95% CI, 1.62–4.93; *P* < 0.001; Table III in the online-only Data Supplement). Symptom-to-reperfusion time, TIMI blush grade, and no ST-segment resolution were not multivariable associates of microvascular obstruction.

Microvascular Infarct Pathologies and Invasive Microvascular Parameters in Combination

The combination of IMR > 40 and CFR ≤ 2.0 was a multivariable associate with microvascular obstruction (OR, 2.28; 95% CI, 1.16–4.46; *P* = 0.016) but not with myocardial hemorrhage (*P* = 0.104).

Compared with IMR > 40 and CFR ≤ 2.0 (reference group), the group with the combination of IMR ≤ 40 and CFR ≤ 2.0 was associated with a reduced odds of microvascular obstruction (OR, 0.19; 95% CI, 0.05–0.76; *P* = 0.019) and myocardial hemorrhage (OR, 0.17; 95% CI, 0.03–0.92; *P* = 0.040).

Microvascular Dysfunction and Subsequent LV Outcomes

Changes in LVEDV

An IMR > 40 was a univariable (regression coefficient, 11.43; 95% CI, 4.07–18.79; *P* = 0.002) and a multivariable (regression coefficient, 7.85; 95% CI, 0.41–15.29; *P* = 0.039) associate of the changes in LVEDV, including after adjustment for infarct size (*n* = 264; Table 4).

Changes in LVEF

An IMR > 40 was a univariable (regression coefficient, −2.89; 95% CI, −4.89 to −0.91; *P* = 0.004, with adjustment for baseline LVEF) and a multivariable (regression coefficient, −2.12; 95% CI, −4.02 to −0.23; *P* = 0.028) associate of the changes in LVEF at 6 months from baseline, including after adjustment for infarct size, as reflected by troponin or contrast-enhanced MRI (*n* = 264; Table IV in the online-only Data Supplement).

LV Outcomes and the Combination of IMR > 40 and CFR ≤ 2.0

Results for the multivariable models for IMR > 40 combined with CFR ≤ 2.0 were not improved compared with the model with IMR > 40 (Tables IV and V in the online-only Data Supplement, footnote).

Microvascular Dysfunction and Longer-Term Health Outcomes

All of the patients (*n* = 283) had completed long-term follow-up data. The median duration of follow-up was of 845 days (range of postdischarge censor duration, 598–1098 days). Thirty patients (11%) died or experienced a first heart failure event during the index hospitalization or after discharge. These events included 5 cardiovascular

Table 1. Clinical and Angiographic Characteristics of 283 Patients With STEMI Categorized According to an IMR≤40 or >40 Measured in the Culprit Coronary Artery at the End of PCI

Characteristics*	All Patients (n=283)	IMR≤40 (n=204, 72%)	IMR>40 (n=79, 28%)	P Value
Age, y	60 (12)	59 (11)	62 (12)	0.093 (‡)
Male sex, n (%)	206 (73)	147 (72)	59 (75)	0.766
BMI, kg/m ²	29 (5)	29 (5)	28 (5)	0.009 (‡)
Medical history, n (%)				
Hypertension	91 (32)	60 (29)	31 (39)	0.120
Current smoking	175 (62)	130 (64)	45 (57)	0.340
Hypercholesterolemia	78 (28)	55 (27)	23 (29)	0.767
Diabetes mellitus†	30 (11)	21 (10)	9 (11)	0.830
Previous angina	32 (11)	22 (11)	10 (13)	0.678
Previous MI	20 (7)	15 (7)	5 (6)	1.000
Previous PCI	14 (5)	9 (4)	5 (6)	0.544
Presenting characteristics				
Heart rate, bpm	78 (17)	78 (17)	78 (16)	0.800 (‡)
Systolic blood pressure, mm Hg	136 (24)	135 (25)	136 (24)	0.797 (‡)
Diastolic blood pressure, mm Hg	79 (14)	79 (14)	80 (13)	0.358 (‡)
Time from symptom onset to reperfusion, min	174 (120–316)	171 (119–300)	179 (129–364)	0.208 (MW)
Ventricular fibrillation,‡ n (%)	19 (7)	11 (5)	8 (10)	0.185
Heart failure, Killip class at presentation, n (%)	201 (71)	158 (80)	43 (54)	
I				
II	62 (22%)	40 (20)	22 (28)	<0.001
III/IV	20 (7)	6 (3)	14 (18)	
ECG				
ST-segment elevation resolution after PCI, n (%)				
Complete, ≥70%	128 (45)	23 (11)	17 (22)	
Incomplete, 30%–<70%	114 (40)	79 (39)	35 (44)	0.022
None, ≤30%	40 (14)	23 (11)	27 (34)	
Reperfusion strategy, n (%)				
Primary PCI	262 (93)	189 (93)	73 (92)	
Rescue PCI (failed thrombolysis)	14 (5)	10 (5)	4 (5)	1.000
Successful thrombolysis	7 (2)	5 (3)	2 (3)	
Coronary angiography				
No. of diseased arteries,§ n (%)				
1	158 (56)	112 (55)	46 (58)	
2	83 (29)	61 (30)	22 (28)	0.973
3	37 (13)	27 (13)	10 (13)	
Culprit artery, n (%)				
LM	5 (2)	4 (2)	1 (1)	
LAD	107 (38)	72 (35)	35 (44)	
LCx	51 (18)	39 (19)	12 (15)	0.371
RCA	125 (44)	93 (46)	32 (40)	

(Continued)

Table 1. Continued

Characteristics*	All Patients (n=283)	IMR≤40 (n=204, 72%)	IMR>40 (n=79, 28%)	P Value
TIMI coronary flow grade before PCI, n (%)				
0/1	204 (72)	141 (69)	63 (80)	
2/3	79 (28)	63 (31)	16 (20)	0.078
TIMI coronary flow grade after PCI, n (%)				
0/1	2 (1)	1 (1)	1 (1)	
2/3	281 (99)	203 (99)	78 (99)	0.481
TIMI frame count before PCI	29.4 (18.0–44.0)	28.0 (18.0–42.4)	35.9 (25.0–52.5)	0.129 (MW)
TIMI frame count after PCI	15.3 (10.0–24.7)	16.9 (8.2–22.6)	20.0 (14.6–29.1)	<0.001 (MW)
TIMI blush grade after PCI				
0/1	71 (26)	43 (22)	28 (38)	0.013
2/3	198 (74)	152 (78)	46 (62)	
Culprit lesion, residual stenosis, %	12.4 (5.5)	12.3 (5.6)	12.5 (5.4)	0.807 (†)
CFR	1.6 (1.1–2.1)	1.6 (1.2–2.2)	1.4 (1.0–1.8)	<0.001
IMR	25 (15–44)	18 (13–26)	56 (48–80)	<0.001
Fractional flow reserve	0.90 (0.10)	0.90 (0.09)	0.94 (0.06)	0.006
Resistive reserve ratio	1.8 (1.4–2.5)	1.9 (1.5–2.6)	1.8 (1.3–2.4)	0.093
Treatment in the catheter laboratory, n (%)				
Aspiration thrombectomy	203 (72)	143 (70)	60 (76)	0.379
Glycoprotein IIb/IIIa inhibitor	259 (92)	185 (91)	74 (94)	0.485
Medical therapy, n (%)				
ACE-I or ARB	279 (99)	200 (98)	79 (100)	0.579
β-Blocker	269 (95)	196 (96)	73 (92)	0.225
Initial blood results on admission				
C-reactive protein, mg/L	4 (2–7)	4 (2–7)	4 (2–7)	0.971 (MW)
Leukocyte cell count, ×10 ⁹ L	12.4 (3.6)	12.3 (3.4)	12.5 (4.0)	0.743 (†)
Platelet count, ×10 ⁶ L	246 (67)	249 (69)	238 (61)	0.193 (†)
Troponin T, ng/L	1566 (93–4411)	1500 (90–3911)	1967 (106–6465)	0.070 (MW)

ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CFR, coronary flow reserve; IMR, index of microvascular resistance; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; LM, left main coronary artery; MI, myocardial infarction; MW, Mann-Whitney; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment–elevation myocardial infarction; and TIMI, Thrombolysis in Myocardial Infarction. Killip classification of heart failure after acute myocardial infarction: class I, no heart failure; class II, pulmonary rales or crepitations, a third heart sound, and elevated jugular venous pressure; class III, acute pulmonary edema; and class IV, cardiogenic shock.

*Data are reported as mean (SD), median (IQR), or n (%) as appropriate. P values have been obtained from a t test, MW test, or Fisher test. TIMI flow grades before and after PCI were grouped as 0/1 versus 2/3 for this analysis.

†Diabetes mellitus was defined as a history of diet-controlled or treated diabetes mellitus.

‡Successfully electrically cardioverted ventricular fibrillation at presentation or during emergency PCI procedure.

§Multivessel coronary artery disease was defined according to the number of stenoses of at least 50% of the reference vessel diameter by visual assessment and whether there was LM stem involvement.

deaths, 3 noncardiovascular deaths, and 22 episodes of heart failure (Killip class 3 or 4 heart failure [n=20] or defibrillator implantation [n=2]). Ten patients (3.5%) died or experienced a first heart failure hospitalization after discharge (Table V in the online-only Data Supplement).

IMR was a univariable associate of all-cause death or heart failure, whereas CFR was not (Table 5). Because of

the number of events observed, 2 multivariable models were considered: 1 model with hypertension and smoking as covariates and 1 model with ST-segment resolution (none) and TIMI frame count (Table 5). In the model with smoking and hypertension, an IMR>40 (OR, 4.70; 95% CI, 2.10–10.53; P<0.001) was a multivariable associate of all-cause death or heart failure. In the model




Figure 2. CONSORT (Consolidated Standards of Reporting Trials) flow diagram of the cohort study.

CFR indicates coronary flow reserve; CMR, cardiac magnetic resonance; IMR, index of microvascular resistance; and STEMI, ST-segment-elevation myocardial infarction.

with ST-segment resolution (none) and TIMI frame count, an IMR>40 was also a multivariable associate with this outcome (OR, 4.42; 95% CI, 1.93–10.10; $P<0.001$). The combination of IMR>40 and CFR≤2.0 did not enhance the magnitude of the prognostic significance of IMR>40 (Table 5).

Fractional Flow Reserve and the Ratio of CFR to Fractional Flow Reserve

Fractional flow reserve measured in the culprit coronary artery was not associated with myocardial hemorrhage status ($P=0.262$), nor was it associated with LVEDV or LVEF at baseline or at follow-up. Fractional flow reserve was not associated with health outcomes. Similar results were observed for the ratio of CFR to fractional flow reserve, which reflects true CFR (Results in the online-only Data Supplement).

DISCUSSION

We have undertaken the largest prospective study of invasive tests of microvascular function, infarct pathology revealed by serial CMR, and spontaneous adverse health outcomes in patients with acute STEMI.

The main findings are the following: (1) Microvascular dysfunction at the end of emergency PCI, as classified by an IMR>40 (without CFR), was more consistently associated with infarct pathology and prognosis than symptom-to-reperfusion time or angiographic and ECG measures of reperfusion; (2) an IMR>40 was more closely associated with myocardial hemorrhage and microvascular obstruction than the combination of an IMR>40 and CFR≤2.0; (3) an IMR>40 was a multivariable associate of the changes in LVEF and LVEDV independently of infarct size; and (4) an IMR>40 identifies patients who have a 4-fold increase in all-cause death

Table 2. CMR Findings at 2 Days and 6 Months After Reperfusion in 283 Patients With STEMI Categorized According to an IMR ≤ 40 or >40 in the Territory of the Culprit Artery at the End of Emergency PCI

Characteristics*	All Patients (n=283)	IMR ≤ 40 (n=145, 51%)	IMR >40 (n=65, 23%)	P Value
CMR findings 2 d after MI				
LVEF, %	55 (10)	56 (9)	51 (10)	<0.001 (†)
LVEDV, mL				
Men	160 (32)	158 (32)	165 (34)	0.190 (†)
Women	124 (25)	126 (23)	120 (29)	0.418 (†)
LV end-systolic volume, mL				
Men	75 (26)	72 (24)	82 (30)	0.020 (MW)
Women	55 (18)	53 (18)	60 (17)	0.130 (MW)
LV mass, g				
Men	141 (123 to 160)	141 (123 to 161)	142 (127 to 152)	0.858 (MW)
Women	95 (85 to 105)	97 (87 to 106)	88 (76 to 104)	0.211 (MW)
Edema and infarct characteristics				
Myocardial edema, % LV mass	32 (12)	30 (11)	37 (13)	<0.001 (†)
Infarct size, % LV mass	16 (7 to 27)	14 (4 to 24)	24 (11 to 34)	<0.001 (†)
Myocardial salvage index, % of LV mass	61 (44 to 85)	68 (50 to 87)	49 (39 to 72)	<0.001 (†)
Late microvascular obstruction, n (%)	142 (50)	88 (43)	54 (68)	<0.001
Late microvascular obstruction, % LV mass	0.1 (0.0 to 3.5)	0.0 (0.0 to 2.4)	2.1 (0.0 to 8.4)	<0.001 (†)
Myocardial hemorrhage, n (%)	89 (42)	51 (34)	38 (58)	0.01
CMR findings 6 mo after MI (n=267)				
LVEF at 6 mo, %	62 (9)	64 (8)	58 (11)	<0.001 (†)
LV end-systolic volume at 6 mo, mL				
Men	61 (42 to 79)	60 (42, 72)	72 (52, 97)	0.004 (MW)
Women	41 (33 to 56)	39 (32, 53)	48 (42, 59)	0.060 (MW)
Change in LVEDV at 6 mo from baseline, mL				
Men	6 (−8 to 21)	4 (−8 to 16)	13 (−2 to 33)	0.024 (MW)
Women	1 (−11 to 10)	0 (−11 to 7)	3 (−13 to 19)	0.524 (MW)

CMR indicates cardiac magnetic resonance; IMR, index of microvascular resistance; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MW, Mann-Whitney; and T1, myocardial longitudinal relaxation time. Area at risk was measured with T2 mapping. Data are given as n (%) or mean (SD). P values were obtained from a *t* test, Mann-Whitney test, or a Fisher test.

*Data are reported as mean (SD), median (IQR), or n (%) as appropriate. LVEF was missing in 24 subjects at follow-up. LVEDV at follow-up was missing in 16 men and 8 women.

or heart failure, whereas CFR (or true CFR) alone was not associated with this outcome and the combination of IMR and CFR had no incremental prognostic value. These results refute our hypothesis that the combination of IMR with CFR would have superior prognostic value.

Implications for Patient Management

Using IMR in patients with acute STEMI, the cardiologist can focus risk stratification with a simple index that has a single cutoff (IMR >40). This test of microvascular dysfunction provides incremental prognostic information over and above infarct size at an early time point before infarct size is disclosed by measurement of tropo-

nin or MRI. This result enhances the clinical relevance of measuring IMR in patients with acute STEMI. CFR, either alone or in combination with IMR, is not needed, and a more complicated combined approach with both measures is not necessary.

Our study adds to the literature on the invasive assessments of the efficacy of myocardial reperfusion in patients with acute STEMI.^{11–13,20–22,47} Fearon et al¹³ established that an IMR >40 was independently associated with all-cause mortality and heart failure; however, information on LV function and infarct pathology was not described, and the IMR threshold of 40 lacks validation against infarct pathology and LV outcomes. Our

Table 3. Multivariable Associations Between Clinical Characteristics, IMR>40 at the End of Emergency PCI, and the Occurrence of Myocardial Hemorrhage 2 Days Later (n=200) in Patients With Acute STEMI

Binary Logistic Regression	OR (95% CI)	P Value
IMR>40	2.86 (1.52–5.39)	0.001
Male sex	2.75 (1.32–5.72)	0.007
Smoker	2.08 (1.11–3.90)	0.023
Hypertension	1.98 (1.04–3.74)	0.037
Harrell C statistic	0.684	

CI indicates confidence interval; IMR, index of microvascular resistance; and OR, odds ratio. Manual backward selection was used with a *P* value threshold of 0.10 for inclusion. Previous percutaneous coronary intervention was excluded because numeric instability. The multivariable association for IMR>40 and coronary flow reserve ≤ 2.0 with myocardial hemorrhage was 2.51 (95% CI, 1.28–4.91; *P*=0.007; Harrell C statistic=0.671).

study includes new information with serial CMR. We have shown that an IMR>40 is independently associated with infarct pathology, changes in LV function and volume, and all-cause-death or heart failure. On the other hand, the prognostic significance of CFR was less than that of IMR, and CFR was not additive to IMR. CFR has greater hemodynamic dependence; it is subject to variations in resting flow, is not specific for the microvasculature, and has a narrower range of values.^{14,48}

CFR reflects the functional (vasodilator) capacity of the coronary artery circulation,⁴⁸ whereas IMR reflects microvascular resistance. Park et al¹⁶ undertook a prognostic study of IMR and CFR in 89 patients with acute STEMI. They found that the combination of an increased IMR and reduced CFR was associated with changes in LV wall motion score index at 3 months as revealed by echocardiography and major adverse cardiac and cerebrovascular events. The results of this study lend support to the theory that the combination of IMR and CFR might have additive prognostic value compared with either index alone. Compared with the study by Park et al,¹⁶ our study included a population that was 3 times larger, advanced cardiac imaging with MRI, independent analysis of spontaneous adverse cardiac events, and a composite outcome that did not include revascularization. Furthermore, another small study (n=40)¹⁸ in patients with acute STEMI showed that the combination of high IMR and low CFR enhanced the predictive accuracy of detecting microvascular obstruction compared with either index alone. The results from our study refute those of Park et al¹⁶ and Ahn et al¹⁸ and indicate that an IMR>40 is sufficient for prognostication.

In the acute clinical setting, failed myocardial reperfusion, as reflected by microvascular obstruction and myocardial hemorrhage, occurs in about half of all patients with STEMI and commonly passes undetected acutely.

Microvascular obstruction is potentially reversible,⁴ but without successful myocardial reperfusion, severe vascular damage progresses to irreversible myocardial hemorrhage in 40% of all patients.^{3–5} When CMR is performed days later, it is too late for early intervention to prevent or treat severe microvascular damage, and CMR has limited availability in routine practice.

An IMR>40 was consistently associated with infarct pathology, changes in LV function and volumes independently of infarct size, and all-cause death or

Table 4. Multivariable Associations Between an IMR>40 and Changes in LVEDV at 6 Months From Baseline (n=264)

Linear Regression	Coefficient (95% CI)	P Value
Baseline LVEDV	−0.23 (−0.35 to −0.12)	<0.001
Infarct size	1.03 (0.75 to 1.30)	<0.001
BMI	1.16 (0.41 to 1.90)	0.003
Hypercholesterolemia	−10.55 (−18.13 to −2.97)	0.007
Male sex	11.27 (3.05 to 19.49)	0.007
IMR>40	7.85 (0.41 to 15.29)	0.039
Diabetes mellitus	−10.15 (−20.24 to −0.06)	0.049
TIMI blush grade 2/3 after PCI	−6.06 (−13.21 to 1.08)	0.096
Hypertension	5.13 (−1.99 to 12.25)	0.157
TIMI frame count after PCI	−0.16 (−0.42 to 0.11)	0.241
Heart rate	−0.10 (−0.30 to 0.09)	0.298
Previous PCI	−8.63 (−25.80 to 8.55)	0.323
Age	−0.14 (−0.47 to 0.19)	0.410
Smoker	3.00 (−4.22 to 10.23)	0.413
Culprit lesion, percentage residual stenosis	0.09 (−0.51 to 0.70)	0.758
Symptom-to-reperfusion time per 10 min	0.01 (−0.13 to 0.15)	0.894
Previous MI	−0.48 (−16.18 to 15.21)	0.952
Previous angina	−0.23 (−10.56 to 10.09)	0.965
SBP per 10 mm Hg	−0.01 (−1.35 to 1.32)	0.984
Bayesian information criterion	2137	

BMI indicates body mass index; CI, confidence interval; IMR, index of microvascular resistance; LVEDV, left ventricular end-diastolic volume; MI, myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; and TIMI, Thrombolysis in Myocardial Infarction. A combination of IMR>40 and CFR ≤ 2.0 was not a multivariable associate of the change in LVEDV at 6 months from baseline when infarct size (percent LV mass) was included in the model (*P*=0.059). In a model that included peak troponin ($\mu\text{g/L}$), the multivariable association for IMR>40 and CFR ≤ 2.0 with the change in LVEDV at 6 months from baseline was 10.68 (95% CI, 2.23–19.12; *P*=0.014; Bayesian information criterion=2080). According to the Bayesian information criteria, there was no improvement in the model that included IMR>40 and CFR ≤ 2.0 .

Table 5. Relationships Between IMR and CFR and All-Cause Death or First Hospitalization for Heart Failure During or After the Index Hospitalization Obtained With Logistic Regression

Associations	OR (95% CI)	P Value
Univariable associations		
IMR>40	4.36 (2.10–9.06)	<0.001
IMR (for a 5-unit change)	1.08 (1.05–1.12)	<0.001
IMR>median	2.16 (1.01–4.61)	0.047
CFR≤2.0, IMR>40	4.37 (2.13–8.97)	<0.001
CFR≤median, IMR>median	2.96 (1.24–7.08)	0.015
CFR (for a 0.2-unit change)	0.92 (0.82–1.02)	0.124
CFR≤median	1.74 (0.81–3.72)	0.153
CFR≤2.0	1.17 (0.50–2.72)	0.721
Multivariable associations		
Model A (n=283)		
IMR>40	4.70 (2.10–10.53)	<0.001
Cigarette smoker	2.49 (1.01–6.14)	0.048
Hypertension	2.84 (1.26–6.42)	0.012
IMR>40, CFR ≤2.0	5.01 (2.22–11.33)	<0.001
Cigarette smoker	2.69 (1.08–6.69)	0.033
Hypertension	2.84 (1.26–6.42)	0.12
Model B (n=282)		
IMR >40	4.42 (1.93–10.10)	<0.001
No ST-segment resolution	2.49 (1.01–6.15)	0.049
TIMI frame count after PCI	1.00 (0.97–1.03)	0.823
IMR>40, CFR≤2.0	4.46 (1.96–10.15)	<0.001
No ST-segment resolution	2.58 (1.04–6.38)	0.041
TIMI frame count after PCI	1.00 (0.97–1.03)	0.866

CFR indicates coronary flow reserve; CI, confidence interval; IMR, index of microvascular resistance; OR, odds ratio; PCI, percutaneous coronary intervention; and TIMI, Thrombolysis in Myocardial Infarction. The median duration of follow-up was 845 days (postdischarge censor duration range, 598–1098 days). Thirty patients (10.4%) died or experienced an index heart failure event.

heart failure compared with other standard measures of reperfusion injury, including TIMI frame count, TIMI myocardial perfusion grade, and ST-segment resolution.^{24,49} In our population, a minority of patients (14%) had no evidence of ST-segment resolution 60 minutes after reperfusion, yet microvascular obstruction and myocardial hemorrhage occurred in 50% and 42% of patients, respectively. TIMI myocardial perfusion grade was not associated with clinical outcomes (Table 5) and is difficult to reliably measure in clinical practice. Reliable measurement of failed reperfusion at the end of the PCI procedure is therefore a difficult clinical conundrum, not least because coronary reper-

fusion is successfully achieved in the majority of all patients.

Our results have important clinical implications. Failed myocardial reperfusion in patients with acute STEMI is common, is associated with adverse outcome, and often goes unnoticed, largely because current assessment methods lack sensitivity and routine CMR, usually performed days after the acute event, is often not practical or cost-efficient. Immediate detection of failed myocardial reperfusion becomes feasible with IMR, is safe,⁵⁰ and allows direct stratification of the highest-risk patients at the time of emergency reperfusion, when early therapeutic interventions may yield the greatest clinical benefit. Conversely, the possibility remains that an IMR>40 may represent an unmodifiable marker of elevated risk.

Implications for Therapy and Clinical Trials

Further research is warranted to investigate preventive or therapeutic interventions in patients stratified by IMR to assess whether IMR-guided strategies might improve prognosis compared with standard care.

Our results provide evidence both for and against IMR as identifying modifiable risk (hence a target for treatment) as opposed to being only an unmodifiable marker of elevated risk (and hence not a target for treatment). The modifiable associations include myocardial salvage index, microvascular obstruction, and myocardial hemorrhage (all of which are linked to the pathophysiology of LV remodeling), and nonmodifiable associations (eg, body mass index, Killip class at presentation, area at risk [myocardial edema] which are essentially markers for increased myocardial mass at risk). Although IMR might offer an opportunity to guide therapy, it may mostly reflect a larger area at risk and thus be unmodifiable. Only an outcomes-based, randomized, controlled trial will decide the issue.

There is some evidence that IMR is responsive to the effects of treatments known to have favorable cardiovascular effects, including vasodilators⁵¹ and anti-ischemic⁵² therapies. During PCI, compared with a direct stenting approach without initial balloon angioplasty, a predilatation step to disrupt and modify the plaque before stenting is associated with a higher IMR at the end of the PCI procedure.⁵³ In the setting of acute STEMI, a randomized trial of initial antiplatelet therapy in 76 patients undergoing primary PCI disclosed that, compared with an oral loading dose of 600 mg clopidogrel, an oral loading dose of 180 mg ticagrelor was associated with a lower IMR at the end of the procedure (22.2±18.0 versus 34.4±18.8 U; $P=0.005$).⁵⁴ In other randomized, controlled trials in acute MI, IMR is being used to assess the comparative efficacy of antiplatelet therapies⁵⁵ (NCT0273334), vasodilator therapy,⁵⁶ and low-dose intracoronary thrombolysis (T-TIME [A Trial of Low-Dose Adjunctive alteplase During Primary PCI]; NCT02257294).

Sample Size Calculation and Clinical Trials

In addition to the study design, estimated treatment effect, and power, the key factor that will influence the sample size in a clinical trial in which IMR is used as measure of treatment effect is the variance in IMR for the population studied. T-TIME is a randomized, placebo-controlled trial of 2 reduced doses of alteplase (10 and 20 mg) administered directly into the culprit coronary artery after reperfusion but before stent implantation. In that trial, we have estimated that if the median IMR is 33.9 (SD, 25.2) and the IMR values are 27.2 and 20.5 in the 10- and 20-mg dose groups, respectively, then 80 subjects per group would be needed. This calculation is based on an average difference in IMR between treatment and placebo of 10, assuming that there is a linear trend with dose. If the average difference in IMR between treatment and placebo is 13, then 48 subjects per group would be needed.

Limitations

We performed a single-center, natural-history study. The median IMR in our population was 25, which is comparable to previous IMR values in some^{12,23} but not all^{11,13} cohorts of patients with STEMI. IMR is associated with infarct size¹¹ and potentially the duration of ischemia. The ischemic time in our population was relatively short (Table 1), which potentially explains IMR distribution in our population. There was a comparatively lower proportion of patients with an anterior STEMI in our cohort (37% of patients) compared with, for example, 49% of cases in the study by McGeoch et al¹¹ (median IMR, 35) and 55% of cases in the study by Fearon et al¹³ (median IMR, 31). These studies involved fewer patients, and enrollment may have been more selective. IMR measurement involves a diagnostic guidewire and use of intravenous adenosine and may prolong the procedure by ~5 minutes. In 2013, the US Food and Drug Administration issued a safety announcement on the risk of MI and death in patients receiving Adenoscan (adenosine) for stress testing. However, a subsequent prospective, multicenter study has shown that intravenous adenosine when administered briefly for invasive physiology testing is safe and well tolerated in patients with acute or recent MI.⁵⁰ IMR was measured routinely in our catheter laboratories, with measurements obtained by all of the cardiologists (n=13) without complication and in the setting of routine emergency care.

Most of the adverse events occurred initially during the index hospitalization. The limited number of adverse events constrained the statistical power of the multivariable models of adverse health outcomes. The study population included 21 patients initially treated with thrombolysis, and 14 of these patients had rescue PCI. The main results of our study were unchanged when these patients were removed (data not shown). The limited

number of adverse events constrained the number of variables and related statistical power in the prognostic models. Our analysis does not permit inference on causality, and further studies are warranted.

Conclusions

Compared with the angiographic and ECG measures of reperfusion, the combination of IMR>40 and CFR≤2.0, and CFR alone, an IMR>40 is consistently and strongly associated with microvascular pathology, changes in LV function and volumes, and all-cause death and heart failure in the longer term. Our results validate previous investigations and support further research into IMR-based therapeutic strategies.

ACKNOWLEDGMENTS

The authors thank the patients who participated in this study and the staff in the Cardiology and Radiology departments. The authors thank Peter Weale and Patrick Revell (Siemens Healthcare, UK).

SOURCES OF FUNDING

This work was supported by the British Heart Foundation Center of Research Excellence Award (RE/13/5/30177), the British Heart Foundation Project grant PG/11/2/28474, the National Health Service, and the Chief Scientist Office. Dr Berry was supported by a Senior Fellowship from the Scottish Funding Council. Dr Welsh is supported by British Heart Foundation Fellowship FS/12/62/29889.

DISCLOSURES

On the basis of institutional agreements with the University of Glasgow, Siemens Healthcare has provided work-in-progress imaging methods, and Dr Berry has acted as a consultant to St. Jude Medical. Dr Oldroyd has acted as consultant to St. Jude Medical and Volcano Corporation. These companies had no involvement in the current research or the manuscript. The other authors report no conflicts.

AFFILIATIONS

From BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences (D.C., N.A., J.C., V.T.Y.M., M.M., M.C.P., I.M., A.R., K.G.O., C.B.), and Robertson Centre for Biostatistics (C.H., I.F.), University of Glasgow, Glasgow, UK; and West of Scotland Heart and Lung Centre, Golden Jubilee National Hospital, Clydebank, UK (D.C., N.A., J.C., V.T.Y.M., M.M., M.C.P., H.E., M.L., S.H., S.W., A.D., A.M., I.M., K.G.O., C.B.).

FOOTNOTES

Received March 21, 2016; accepted October 5, 2016.

The online-only Data Supplement is available with this article at <http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.116.022603/-/DC1>.

Circulation is available at <http://circ.ahajournals.org>.

REFERENCES

- Mangion K, Corcoran D, Carrick D, Berry C. New perspectives on the role of cardiac magnetic resonance imaging to evaluate myocardial salvage and myocardial hemorrhage after acute reperfused ST-elevation myocardial infarction. *Expert Rev Cardiovasc Ther*. 2016;14:843–854. doi: 10.1586/14779072.2016.1173544.
- Fröhlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial reperfusion injury: looking beyond primary PCI. *Eur Heart J*. 2013;34:1714–1722. doi: 10.1093/eurheartj/ehd090.
- Eitel I, de Waha S, Wöhrle J, Fuernau G, Lurz P, Pauschinger M, Desch S, Schuler G, Thiele H. Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2014;64:1217–1226. doi: 10.1016/j.jacc.2014.06.1194.
- Carrick D, Haig C, Ahmed N, McEntegart M, Petrie MC, Eteiba H, Hood S, Watkins S, Lindsay MM, Davie A, Mahrous A, Mordi I, Rauhalammi S, Sattar N, Welsh P, Radjenovic A, Ford I, Oldroyd KG, Berry C. Myocardial hemorrhage after acute reperfused ST-segment-elevation myocardial infarction: relation to microvascular obstruction and prognostic significance. *Circ Cardiovasc Imaging*. 2016;9:e004148. doi: 10.1161/CIRCIMAGING.115.004148.
- Carrick D, Haig C, Rauhalammi S, Ahmed N, Mordi I, McEntegart M, Petrie MC, Eteiba H, Hood S, Watkins S, Lindsay M, Mahrous A, Ford I, Tzemos N, Sattar N, Welsh P, Radjenovic A, Oldroyd KG, Berry C. Prognostic significance of infarct core pathology revealed by quantitative non-contrast in comparison with contrast cardiac magnetic resonance imaging in reperfused ST-elevation myocardial infarction survivors. *Eur Heart J*. 2016;37:1044–1059. doi: 10.1093/eurheartj/ehv372.
- de Waha S, Desch S, Eitel I, Fuernau G, Zachrau J, Leuschner A, Gutberlet M, Schuler G, Thiele H. Impact of early vs. late microvascular obstruction assessed by magnetic resonance imaging on long-term outcome after ST-elevation myocardial infarction: a comparison with traditional prognostic markers. *Eur Heart J*. 2010;31:2660–2668. doi: 10.1093/eurheartj/ehq247.
- van 't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade: Zwolle Myocardial Infarction Study Group. *Circulation*. 1998;97:2302–2306.
- Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van De Werf F, Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. *Circulation*. 2000;101:125–130.
- Nijveldt R, Beek AM, Hirsch A, Stoel MG, Hofman MB, Umans VA, Algra PR, Twisk JW, van Rossum AC. Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. *J Am Coll Cardiol*. 2008;52:181–189. doi: 10.1016/j.jacc.2008.04.006.
- Fearon WF, Shah M, Ng M, Brinton T, Wilson A, Tremmel JA, Schnittger I, Lee DP, Vagelos RH, Fitzgerald PJ, Yock PG, Yeung AC. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2008;51:560–565. doi: 10.1016/j.jacc.2007.08.062.
- McGeoch R, Watkins S, Berry C, Steedman T, Davie A, Byrne J, Hillis S, Lindsay M, Robb S, Dargie H, Oldroyd K. The index of microcirculatory resistance measured acutely predicts the extent and severity of myocardial infarction in patients with ST-segment elevation myocardial infarction. *JACC Cardiovasc Interv*. 2010;3:715–722. doi: 10.1016/j.jcin.2010.04.009.
- Payne AR, Berry C, Doolin O, McEntegart M, Petrie MC, Lindsay MM, Hood S, Carrick D, Tzemos N, Weale P, McComb C, Foster J, Ford I, Oldroyd KG. Microvascular resistance predicts myocardial salvage and infarct characteristics in ST-elevation myocardial infarction. *J Am Heart Assoc*. 2012;1:e002246. doi: 10.1161/JAHA.112.002246.
- Fearon WF, Low AF, Yong AS, McGeoch R, Berry C, Shah MG, Ho MY, Kim HS, Loh JP, Oldroyd KG. Prognostic value of the index of microcirculatory resistance measured after primary percutaneous coronary intervention. *Circulation*. 2013;127:2436–2441. doi: 10.1161/CIRCULATIONAHA.112.000298.
- Barbato E, Aarnoudse W, Aengevaeren WR, Werner G, Klauss V, Bojara W, Herzfeld I, Oldroyd KG, Pijls NH, De Bruyne B; Week 25 Study Group. Validation of coronary flow reserve measurements by thermodilution in clinical practice. *Eur Heart J*. 2004;25:219–223. doi: 10.1016/j.ehj.2003.11.009.
- van de Hoef TP, van Lavieren MA, Damman P, Delewi R, Piek MA, Chamuleau SA, Voskuil M, Henriques JP, Koch KT, de Winter RJ, Spaan JA, Siebes M, Tijssen JG, Meuwissen M, Piek JJ. Physiological basis and long-term clinical outcome of discordance between fractional flow reserve and coronary flow velocity reserve in coronary stenoses of intermediate severity. *Circ Cardiovasc Interv*. 2014;7:301–311.
- Park SD, Baek YS, Lee MJ, Kwon SW, Shin SH, Woo SI, Kim DH, Kwan J, Park KS. Comprehensive assessment of microcirculation after primary percutaneous intervention in ST-segment elevation myocardial infarction: insight from thermodilution-derived index of microcirculatory resistance and coronary flow reserve. *Coron Artery Dis*. 2016;27:34–39. doi: 10.1097/MCA.0000000000000310.
- Carrick D, Haig C, Carberry J, May VT, McCartney P, Welsh P, Ahmed N, McEntegart M, Petrie MC, Eteiba H, Lindsay M, Hood S, Watkins S, Mahrous A, Rauhalammi SM, Mordi I, Ford I, Radjenovic A, Sattar N, Oldroyd KG, Berry C. Microvascular resistance of the culprit coronary artery in acute ST-elevation myocardial infarction. *JCI Insight*. 2016;1:e85768. doi: 10.1172/jci.insight.85768.
- Ahn SG, Hung OY, Lee JW, Lee JH, Youn YJ, Ahn MS, Kim JY, Yoo BS, Lee SH, Yoon J, Kwon W, Samady H. Combination of the thermodilution-derived index of microcirculatory resistance and coronary flow reserve is highly predictive of microvascular obstruction on cardiac magnetic resonance imaging after ST-segment elevation myocardial infarction. *JACC Cardiovasc Interv*. 2016;9:793–801. doi: 10.1016/j.jcin.2015.12.025.
- Cuculi F, Dall'Armellina E, Manliot C, De Caterina AR, Colyer S, Ferreira V, Morovat A, Prendergast BD, Forfar JC, Alp NJ, Choudhury RP, Neubauer S, Channon KM, Banning AP, Kharbanda RK. Early change in invasive measures of microvascular function can predict myocardial recovery following PCI for ST-elevation myocardial infarction. *Eur Heart J*. 2014;35:1971–1980. doi: 10.1093/eurheartj/ehd434.
- Cuculi F, De Maria GL, Meier P, Dall'Armellina E, de Caterina AR, Channon KM, Prendergast BD, Choudhury RP, Choudhury RC, Forfar JC, Kharbanda RK, Banning AP. Impact of microvascular obstruction on the assessment of coronary flow reserve, index of microcirculatory resistance, and fractional flow reserve after ST-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2014;64:1894–1904. doi: 10.1016/j.jacc.2014.07.987.
- Kitabata H, Imanishi T, Kubo T, Takarada S, Kashiwagi M, Matsumoto H, Tsujioka H, Ikejima H, Arita Y, Okochi K, Kuroi A, Ueno S, Kataiwa H, Tanimoto T, Yamano T, Hirata K, Nakamura N, Tanaka A, Mizukoshi M, Akasaka T. Coronary microvascular resistance index immediately after primary percutaneous coronary intervention as a predictor of the transmural extent of infarction in patients with ST-segment elevation anterior acute myocardial infarction.

- JACC Cardiovasc Imaging*. 2009;2:263–272. doi: 10.1016/j.jcmg.2008.11.013.
22. Sezer M, Aslanger EK, Cimen AO, Yormaz E, Turkmen C, Umman B, Nisanci Y, Bugra Z, Adalet K, Umman S. Concurrent microvascular and infarct remodeling after successful reperfusion of ST-elevation acute myocardial infarction. *Circ Cardiovasc Interv*. 2010;3:208–215. doi: 10.1161/CIRCINTERVENTIONS.109.891739.
 23. Ito N, Nanto S, Doi Y, Sawano H, Masuda D, Yamashita S, Okada K, Kaibe S, Hayashi Y, Kai T, Hayashi T. High index of microcirculatory resistance level after successful primary percutaneous coronary intervention can be improved by intracoronary administration of nicorandil. *Circ J*. 2010;74:909–915.
 24. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;127:e362–e425. doi: 10.1161/CIR.0b013e3182742cf6.
 25. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation*. 2011;124:e574–e651. doi: 10.1161/CIR.0b013e31823ba622.
 26. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E; Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. *J Cardiovasc Magn Reson*. 2013;15:91. doi: 10.1186/1532-429X-15-91.
 27. Carrick D, Haig C, Rauhalammi S, Ahmed N, Mordil I, McEntegart M, Petrie MC, Eteiba H, Lindsay M, Watkins S, Hood S, Davie A, Mahrous A, Sattar N, Welsh P, Tzemos N, Radjenovic A, Ford I, Oldroyd KG, Berry C. Pathophysiology of LV remodeling in survivors of STEMI: inflammation, remote myocardium, and prognosis. *JACC Cardiovasc Imaging*. 2015;8:779–789. doi: 10.1016/j.jcmg.2015.03.007.
 28. Giri S, Chung YC, Merchant A, Mihai G, Rajagopalan S, Raman SV, Simonetti OP. T2 quantification for improved detection of myocardial edema. *J Cardiovasc Magn Reson*. 2009;11:56. doi: 10.1186/1532-429X-11-56.
 29. Verhaert D, Thavendiranathan P, Giri S, Mihai G, Rajagopalan S, Simonetti OP, Raman SV. Direct T2 quantification of myocardial edema in acute ischemic injury. *JACC Cardiovasc Imaging*. 2011;4:269–278. doi: 10.1016/j.jcmg.2010.09.023.
 30. Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. *Magn Reson Med*. 2002;47:372–383.
 31. Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V, Moon JC. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. *JACC Cardiovasc Imaging*. 2011;4:150–156. doi: 10.1016/j.jcmg.2010.11.015.
 32. Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, Schuler G, Thiele H. Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. *J Am Coll Cardiol*. 2010;55:2470–2479. doi: 10.1016/j.jacc.2010.01.049.
 33. Berry C, Kellman P, Mancini C, Chen MY, Bandettini WP, Lowrey T, Hsu LY, Aletras AH, Arai AE. Magnetic resonance imaging delineates the ischemic area at risk and myocardial salvage in patients with acute myocardial infarction. *Circ Cardiovasc Imaging*. 2010;3:527–535. doi: 10.1161/CIRCIMAGING.109.900761.
 34. Payne AR, Casey M, McClure J, McGeoch R, Murphy A, Woodward R, Saul A, Bi X, Zuehlsdorff S, Oldroyd KG, Tzemos N, Berry C. Bright-blood T2-weighted MRI has higher diagnostic accuracy than dark-blood short tau inversion recovery MRI for detection of acute myocardial infarction and for assessment of the ischemic area at risk and myocardial salvage. *Circ Cardiovasc Imaging*. 2011;4:210–219. doi: 10.1161/CIRCIMAGING.110.960450.
 35. Francone M, Bucciarelli-Ducci C, Carbone I, Canali E, Scardala R, Calabrese FA, Sardella G, Mancione M, Catalano C, Fedele F, Passariello R, Bogaert J, Agati L. Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with ST-segment elevation myocardial infarction: insight from cardiovascular magnetic resonance. *J Am Coll Cardiol*. 2009;54:2145–2153. doi: 10.1016/j.jacc.2009.08.024.
 36. van Kranenburg M, Magro M, Thiele H, de Waha S, Eitel I, Cochet A, Cottin Y, Atar D, Buser P, Wu E, Lee D, Bodi V, Klug G, Metzler B, Delewi R, Bernhardt P, Rottbauer W, Boersma E, Zijlstra F, van Geuns RJ. Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patients. *JACC Cardiovasc Imaging*. 2014;7:930–939. doi: 10.1016/j.jcmg.2014.05.010.
 37. Ghugre NR, Ramanan V, Pop M, Yang Y, Barry J, Qiang B, Connelly KA, Dick AJ, Wright GA. Quantitative tracking of edema, hemorrhage, and microvascular obstruction in subacute myocardial infarction in a porcine model by MRI. *Magn Reson Med*. 2011;66:1129–1141. doi: 10.1002/mrm.22855.
 38. Kandler D, Lücke C, Grothoff M, Andres C, Lehmkuhl L, Nitzsche S, Riese F, Mende M, de Waha S, Desch S, Lurz P, Eitel I, Gutberlet M. The relation between hypointense core, microvascular obstruction and intramyocardial haemorrhage in acute reperfused myocardial infarction assessed by cardiac magnetic resonance imaging. *Eur Radiol*. 2014;24:3277–3288. doi: 10.1007/s00330-014-3318-3.
 39. O'Regan DP, Ariff B, Neuwirth C, Tan Y, Durighel G, Cook SA. Assessment of severe reperfusion injury with T2* cardiac MRI in patients with acute myocardial infarction. *Heart*. 2010;96:1885–1891. doi: 10.1136/hrt.2010.200634.
 40. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. *Eur Heart J*. 2001;22:2171–2179.
 41. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van't Hof A, Widimsky P, Zahger D. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2012; 33:2569–2619.
 42. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings: TIMI Study Group. *N Engl J Med*. 1985;312:932–936. doi: 10.1056/NEJM198504043121435.
 43. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. TIMI frame count: a quantitative method of assessing coronary artery flow. *Circulation*. 1996;93:879–888.
 44. Gibson CM, Karha J, Giugliano RP, Roe MT, Murphy SA, Harrington RA, Green CL, Schweiger MJ, Miklin JS, Baran KW, Palmeri S, Braunwald E, Krucoff MW; INTEGRITY Study Group. Association of

- the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. *Am Heart J*. 2004;147:847–852. doi: 10.1016/j.ahj.2003.11.015.
45. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Katus HA, Lindahl B, Morrow DA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. *Circulation*. 2012;126:2020–2035. doi: 10.1161/CIR.0b013e31826e1058.
 46. Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE, Targum SL; American College of Cardiology; American Heart Association. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). *Circulation*. 2015;132:302–361. doi: 10.1161/CIR.0000000000000156.
 47. Lim HS, Yoon MH, Tahk SJ, Yang HM, Choi BJ, Choi SY, Sheen SS, Hwang GS, Kang SJ, Shin JH. Usefulness of the index of microcirculatory resistance for invasively assessing myocardial viability immediately after primary angioplasty for anterior myocardial infarction. *Eur Heart J*. 2009;30:2854–2860. doi: 10.1093/eurheartj/ehp313.
 48. Layland J, Carrick D, Lee M, Oldroyd K, Berry C. Adenosine: physiology, pharmacology, and clinical applications. *JACC Cardiovasc Interv*. 2014;7:581–591. doi: 10.1016/j.jcin.2014.02.009.
 49. van 't Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction: Zwolle Myocardial infarction Study Group. *Lancet*. 1997;350:615–619.
 50. Ahmed N, Layland J, Carrick D, Petrie MC, McEntegart M, Eteiba H, Hood S, Lindsay M, Watkins S, Davie A, Mahrous A, Carberry J, Teng V, McConnachie A, Curzen N, Oldroyd KG, Berry C. Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction. *Int J Cardiol*. 2016;202:305–310. doi: 10.1016/j.ijcard.2015.09.014.
 51. Mangiacapra F, Peace AJ, Di Serafino L, Pyxaras SA, Bartunek J, Wyffels E, Heyndrickx GR, Wijns W, De Bruyne B, Barbato E. Intracoronary Enalaprilat to Reduce MICROvascular Damage During Percutaneous Coronary Intervention (ProMicro) study. *J Am Coll Cardiol*. 2013;61:615–621. doi: 10.1016/j.jacc.2012.11.025.
 52. Kostic J, Djordjevic-Dikic A, Dobric M, Milasinovic D, Nedeljkovic M, Stojkovic S, Stepanovic J, Tesic M, Trifunovic Z, Zamaklar-Tifunovic D, Radosavljevic-Radovanovic M, Ostojic M, Beleslin B. The effects of nicorandil on microvascular function in patients with ST segment elevation myocardial infarction undergoing primary PCI. *Cardiovasc Ultrasound*. 2015;13:26. doi: 10.1186/s12947-015-0020-9.
 53. Cuisset T, Hamilos M, Melikian N, Wyffels E, Sarma J, Sarno G, Barbato E, Bartunek J, Wijns W, De Bruyne B. Direct stenting for stable angina pectoris is associated with reduced periprocedural microcirculatory injury compared with stenting after predilation. *J Am Coll Cardiol*. 2008;51:1060–1065. doi: 10.1016/j.jacc.2007.11.059.
 54. Park SD, Lee MJ, Baek YS, Kwon SW, Shin SH, Woo SI, Kim DH, Kwan J, Park KS. Randomised trial to compare a protective effect of Clopidogrel Versus Ticagrelor on coronary Microvascular injury in ST-segment Elevation myocardial infarction (CV-TIME trial). *Euro-Intervention*. 2016;12:e964–e971. doi: 10.4244/EIJV12I8A159.
 55. Janssens GN, van Leeuwen MA, van der Hoeven NW, de Waard GA, Nijveldt R, Diletti R, Zijlstra F, von Birgelen C, Escaned J, Valgimigli M, van Royen N. Reducing microvascular dysfunction in revascularized patients with ST-elevation myocardial infarction by off-target properties of ticagrelor versus prasugrel: rationale and design of the REDUCE-MVI Study. *J Cardiovasc Transl Res*. 2016;9:249–256. doi: 10.1007/s12265-016-9691-3.
 56. Liou K, Jepson N, Buckley N, Chen V, Thomas S, Russell EA, Ooi SY. Design and rationale for the Endothelin-1 Receptor Antagonism in the Prevention of Microvascular Injury in Patients with non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (ENDORA-PCI) Trial. *Cardiovasc Drugs Ther*. 2016;30:169–175. doi: 10.1007/s10557-016-6641-x.